Showing 121-130 of 7546 results for "".
Elections and Markets, Encore and Biofrontera Launches, More
https://practicaldermatology.com/topics/practice-management/dermwiretv-elections-and-markets-encore-and-biofrontera-launches-more/18564/Election years bring market uncertainty, but should you be making any changes to your portfolio now? Financial experts weigh in on why—no matter the results—there's no need for panic. Allergan launches a new campaign, ActuallySheCan, to empower young women. Several new products are now available forRepresentation in Marketing and Outreach
https://practicaldermatology.com/series/diversity-and-equity-in-dermatology/representation-in-marketing-and-outreach/19916/There is an apparent low rate of participation in aesthetic procedures among patients of color. Does this reflect a lack of interest or does limited representation in marketing and educational materials leave patients feeling that aesthetic interventions aren't meant for them? Panelists discuss theTaking “picture perfect” before and after photos
https://practicaldermatology.com/topics/practice-management/taking-picture-perfect-before-and-after-photos/19751/You probably know the importance of including before and after photos on your dermatology website. However, you might be wondering how to create a professional looking image gallery without a photographer on call. Check out the latest video from Ekwa Marketing to find out!A Growing Armamentarium for Psoriasis: How to Choose the Right Treatment for Each Patient
https://practicaldermatology.com/topics/psoriasis/a-growing-armamentarium-for-psoriasis-how-to-choose-the-right-treatment-for-each-patient/18214/Erin Boh, MD joins host Joshua Zeichner, MD in this edition of DermTube Journal Club to offer tips for navigating all the new and existing treatment options for patients with moderate to severe psoriasis. With so many effective options on the market, Dr. Boh says it's possible to find the best fit fDupixent, Juvéderm Vollure XC, Bavencio Approvals
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-dupixent-juv-derm-vollure-xc-bavencio-approvals/18698/The FDA has approved Regeneron's injectable Dupixent (dupilumab) to treat adults with moderate-to-severe eczema. It will be marketed by Regeneron and Sanofi Genzyme in the US. Allergan's Juvéderm Vollure XC has received FDA approval based on a pivotal clinical trial in which 59 percent of subjects sApprovals in Psoriasis and Skin Cancer Highlight a Year of Innovation in Skin Disease Management
https://practicaldermatology.com/topics/skin-cancer-photoprotection/approvals-in-psoriasis-and-skin-cancer-highlight-a-year-of-innovation-in-skin-disease-management/21069/After periods of low drug approval rates, the last year brought several new agents to market.Organic vs. Paid Marketing: What Is the Difference and Which Is Better for Your Dermatology Practice?
https://practicaldermatology.com/topics/practice-management/organic-vs-paid-marketing-what-is-the-difference-and-which-is-better-for-your-dermatology-practice/23877/Advertising and marketing, organic and paid, inbound and outbound—which better serve your practice?Social media marketing trends for 2022 and beyond
https://practicaldermatology.com/topics/practice-management/social-media-marketing-trends-for-2022-and-beyond/20095/Social media is no longer the new frontier in digital marketing. It is a vital part of daily life for much of your audience. That means it is an indispensable part of a good marketing strategy for your dermatology practice. This short video from Ekwa Marketing (www.ekwa.com) covers the latest trendsCheckpoint Blockade for Advanced cSCC: Exploring Newer Options
https://practicaldermatology.com/topics/skin-cancer-photoprotection/checkpoint-blockade-for-advanced-cscc-exploring-newer-options/23487/Two newer systemic options on the market provide hope in the fight against advanced cutaneous squamous cell carcinoma.Meeting the Needs of Today's Injectables Market
https://practicaldermatology.com/series/c-suite-chats/meeting-needs-todays-injectables-market/26926/David Moatazedi, president and CEO of Evolus, talks about trends in the injectables market and the needs of younger generations.